Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP
VNDA•EMA positive opinion and FDA review update
July 16 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
- Vanda Pharmaceuticals announces EMA positive opinion for orphan drug designation of imsidolimab for GPP
- Vanda Pharmaceuticals says imsidolimab BLA for GPP is under FDA review with target action date December 12, 2026
